Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium.
Biochem Med (Zagreb). 2011;21(3):254-63. doi: 10.11613/bm.2011.035.
Heart failure (HF) is a frequent chronic disease in elderly people and represents a major health and economic burden. The accurate diagnosis of HF and the identification of high risk patients is mandatory to select the appropriate therapy and care. HF is associated to cardiac remodeling and inflammation and to the release of neurohormones. If natriuretic peptides remain the biomarkers of choice for the diagnosis and the prognosis of HF, several biomarkers related to cardiac remodeling and inflammation are available for testing and may add valuable information for the risk estimation of HF patients and for the selection of the most appropriated therapy. Furthermore, the quest for new efficient biomarkers of cardiac remodeling and inflammation is still ongoing and new candidates have been identified for a potential use in daily clinical practices. However, before their potential translation to routine parameters several challenges ranging form the analytical validation to the cost-effectiveness estimation should be considered.
心力衰竭（HF）是老年人中常见的慢性疾病，也是主要的健康和经济负担。准确诊断 HF 和识别高危患者对于选择适当的治疗和护理至关重要。HF 与心脏重构和炎症以及神经激素的释放有关。虽然利钠肽仍然是 HF 诊断和预后的首选生物标志物，但一些与心脏重构和炎症相关的生物标志物也可用于检测，并可为 HF 患者的风险评估和最合适治疗方案的选择提供有价值的信息。此外，寻找新的有效的心脏重构和炎症生物标志物的研究仍在进行中，已经确定了一些新的候选者，有望在日常临床实践中得到应用。然而，在将这些新的候选者转化为常规参数之前，需要考虑从分析验证到成本效益评估等多个方面的挑战。
